Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

569.88 +4.94 (+0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 460,696
Open 566.96
Bid (Size) 544.20 (40)
Ask (Size) 588.00 (200)
Prev. Close 564.94
Today's Range 566.96 - 580.45
52wk Range 272.12 - 609.35
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
UTHR Q1 Deep Dive: Pipeline Advances and Product Launches Dominate Outlook
Biotechnology company United Therapeutics (NASDAQ:UTHR) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 1.6% year on year to... 
Via StockStory

Performance

YTD
+14.7%
+14.7%
1 Month
-1.3%
-1.3%
3 Month
+20.5%
+20.5%
6 Month
+25.5%
+25.5%
1 Year
+83.4%
+83.4%

More News

Read More
News headline image
UTHR Q1 2026 Earnings Transcript ↗
Via The Motley Fool
United Therapeutics (NASDAQ:UTHR) Shares Dip After Q1 2026 Earnings Miss ↗
Via Chartmill
United Therapeutics Corp. (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate ↗
Via Chartmill
News headline image
United Therapeutics (NASDAQ:UTHR) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
From United Therapeutics Corporation
Via Business Wire
News headline image
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
United Therapeutics (UTHR) Q1 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence
News headline image
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
From United Therapeutics Corporation
Via Business Wire
News headline image
The eVTOL Era is Beginning With Uber and Joby Aviation: What Investors Need to Know ↗
Via The Motley Fool
News headline image
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
UTHR Q4 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Reasons Investors Love United Therapeutics (UTHR)
Via StockStory
Topics Stocks
News headline image
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
From United Therapeutics Corporation
Via Business Wire
News headline image
3 Market-Beating Stocks for Long-Term Investors
Via StockStory
Topics Energy
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
Chips Down, Ackman Up: How Iran, the Fed, and a Viral Post Defined Monday's Market ↗
Via Chartmill
Topics Economy
News headline image
Why United Therapeutics (UTHR) Stock Is Up Today
Via StockStory
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
From United Therapeutics Corporation
Via Business Wire
News headline image
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
Via StockStory
News headline image
Therapeutics Stocks Q4 In Review: United Therapeutics (NASDAQ:UTHR) Vs Peers
Via StockStory
Topics Artificial Intelligence
News headline image
2 Mid-Cap Stocks for Long-Term Investors and 1 We Avoid
Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 569.88
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 05/11/26 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 25.58B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.